Business Wire

Meet Paul Tran, Founder and CEO of Rocketship DTC Brand MANSCAPED™

13.4.2021 16:00:00 EEST | Business Wire | Press release

Share

Today, MANSCAPED™, the global leader in men’s below-the-waist grooming, is cracking the code behind the company’s success with an exclusive introduction to its Founder and CEO, Paul Tran. From early beginnings to ongoing endeavors, Paul maintains a steadfast dedication to creativity, long-term thinking, and lifelong learning. These are just a few key takeaways as we get acquainted with the man leading MANSCAPED’s massive movement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005280/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Paul Tran founded MANSCAPED in 2016 with a mission of moving men forward all over the world. (Photo: Business Wire)

A Born Entrepreneur. Born in Vietnam, Paul grew up with little, but with a big outlook on life. Although he experienced adversity at a young age, and as a first-generation immigrant in America who didn’t speak English, he reflects on his upbringing very fondly. Having nothing and coming from nothing ingrained a sense of ambition in Paul, driving him to make the most of any opportunity and practice empathy always.

After settling in New York, his vocabulary soon expanded beyond “hi” and, albeit the only Asian kid in school, he assimilated quickly among his peers and made friends due to his unassuming demeanor, self-awareness, and good nature. A born entrepreneur, Paul recalls one of his earliest memories from elementary school was when he hosted a raffle every Friday. It was a basic concept with no more than nickels on the table, but a weekly activity his classmates raved about and looked forward to. The popular game enhanced their lives unknowingly, while reaffirming Paul’s inner creative spirit.

Fast forward several years, this undeniable self-starter put himself through college at the University of Southern California where he studied at Marshall School of Business and Viterbi School of Engineering. He parlayed his education into his next ventures, which included launching and selling multiple businesses. One was a revolutionary science-backed skincare brand that provides a non-surgical solution for wrinkles and stretch marks. This was Paul’s first company that tackled taboos in the beauty space, but it most certainly wouldn’t be the last.

The MANSCAPED Movement. Paul launched MANSCAPED in 2016 with a vision of driving the movement that changes the face of men’s grooming. By focusing on the needs of what has, for too long, been a sensitive and often stigmatized subject, MANSCAPED has successfully untapped a vast market of male consumers. The brand not only provides premium tools and products for proper grooming but moves men forward by unlocking their confidence and allowing them to be the best versions of themselves. Paul lives by this mission every single day and envisions a world in the future where MANSCAPED plays a significant part in people’s lives all over the world.

Beyond seeing this vision materialize in real life, Paul thrives on working with his supportive and talented team. He is humble at his core, often highlighting teammates for execution and successes rather than taking any credit. This level of humility is understated but significant, as it flows deep into the organization. As CEO, Paul’s responsibilities are many. He loves overseeing the brand’s innovation and technology as a superior technician himself. He also spearheads the company’s direction as a brilliant strategist and constantly works to further establish MANSCAPED as an employer brand that puts company culture and people first. Ensuring that everyone feels valued, included, and appreciated for their efforts is extremely important to him.

Although at the helm of the entire MANSCAPED Family, Paul is a self-described introvert at heart and enjoys spending time in small groups where we can have meaningful conversations and directly care for his colleagues. His intelligent presentations, inspiring words, and witty humor are experienced by all 150 employees during MANSCAPED’s biweekly company-wide meetings. Calendar notifications go from mundane reminders to sparks of joy on these days. As a winner of Inc. Magazine’s Best Workplaces in 2020, MANSCAPED is a workforce of individuals who are as happy as they are grateful for the environment Paul has created.

A Philanthropic Future. When he gets a sliver of time outside of MANSCAPED, Paul feeds his soul by spending time with his wife and two young children. This dedicated father and loving husband shares a special intellectual curiosity with his family. When their conversations run the gamut, Paul always walks away with a fresh perspective on life and appreciation for how far he has come. His deep-rooted desire to give back and commitment to social responsibility are fundamentals he has brought to MANSCAPED, as well as beliefs he lives by. Just one of his lifelong philanthropic goals is setting up his own foundation to help orphans and underprivileged children in Vietnam, which will be a full circle moment for him and so many others he’s impacted along the way.

About MANSCAPED™:

Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target and Best Buy locations throughout the U.S., with further domestic and international retailers coming soon. For more information, visit the website or follow on Facebook, Instagram, Twitter, TikTok, YouTube, and Triller.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Allison Frazier, Director of Public Relations – MANSCAPED, Inc.
allison@manscaped.com
925-216-2791

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye